Valuation: Sernova Biotherapeutics Inc

Market Cap 47.21M 33.39M 29.2M 26.94M 24.88M 3.18B 48M 322M 126M 1.57B 125M 123M 5.39B P/E 2026 *
-4.17x
P/E 2027 * -3.13x
Enterprise Value 47.21M 33.39M 29.2M 26.94M 24.88M 3.18B 48M 322M 126M 1.57B 125M 123M 5.39B EV / Sales 2026 *
-
EV / Sales 2027 * 9.44x
Free-Float
86.84%
Yield 2026 *
-
Yield 2027 * -
1 day-3.85%
1 week-3.85%
Current month-7.41%
1 month-13.79%
3 months-32.43%
6 months-16.67%
Current year-3.85%
1 week 0.12
Extreme 0.125
0.14
1 month 0.12
Extreme 0.12
0.17
Current year 0.12
Extreme 0.12
0.2
1 year 0.12
Extreme 0.12
0.21
3 years 0.12
Extreme 0.12
0.99
5 years 0.12
Extreme 0.12
2.22
10 years 0.1
Extreme 0.095
2.87
Manager TitleAgeSince
Chief Executive Officer 58 12/08/2024
Director of Finance/CFO 60 11/10/2024
Investor Relations Contact - 11/10/2024
Director TitleAgeSince
Director/Board Member 60 19/04/2012
Director/Board Member - 24/04/2023
Director/Board Member - 01/09/2024
Date Insider Type Main position Quantity % Market Cap.
05-22Option

Director

260,000 0.0748%
05-22Option

Director

173,418 0.0499%
05-22Option

Director

260,000 0.0748%
Change 5-day change 1-year change 3-year change Capi.($)
-3.85%-3.85%-24.24%-87.24% 33.39M
+0.82%+0.99%-15.32%+10.65% 126B
+0.29%+0.70%+2.23%-2.14% 12.9B
-1.52%+2.95%+47.11%+112.20% 8.97B
+4.14%-2.38%-48.62%-71.98% 3.98B
-0.47%-1.34%+20.55%+45.56% 2.7B
+0.61%-7.70%-14.75%-24.08% 1.74B
+0.49%-3.87%-6.10%-23.90% 1.61B
+0.47%+10.24%-60.26%-83.72% 1.49B
Average +0.11%-0.87%-11.05%-13.85% 17.76B
Weighted average by Cap. +0.70%+0.91%-10.95%+12.22%

Financials

2026 *2027 *
Net sales - 5M 3.54M 3.09M 2.85M 2.64M 337M 5.08M 34.09M 13.39M 166M 13.28M 12.99M 571M
Net income -12.83M -9.07M -7.94M -7.32M -6.76M -865M -13.04M -87.45M -34.34M -426M -34.06M -33.32M -1.47B -19.77M -13.98M -12.23M -11.28M -10.42M -1.33B -20.1M -135M -52.94M -657M -52.51M -51.36M -2.26B
Net Debt - -
Logo Sernova Biotherapeutics Inc
Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.
Employees
8
Date Price Change Volume
10/07/26 CA$0.1250 -3.85% 155,027
09/07/26 CA$0.1300 0.00% 110,276
08/07/26 CA$0.1300 0.00% 15,100
07/07/26 CA$0.1300 -3.70% 62,135
06/07/26 CA$0.1350 +3.85% 24,204
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1250CAD
Average target price
0.4500CAD
Spread / Average Target
+260.00%

Quarterly revenue - Rate of surprise